Intersect ENT (XENT) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Intersect ENT (XENT) Tops Q4 EPS by 5c
February 23, 2016 4:05 PM EST
Full Year Revenue Increased 60% Year Over Year; Gross Margin at 80%
MENLO PARK, Calif.--(BUSINESS WIRE)--
Intersect ENT Inc. (NASDAQ: XENT), a company dedicated to improving the
quality of life for patients with ear, nose and throat conditions, today
reported financial results for the fourth quarter and year
ended December 31, 2015.
Fourth quarter revenue was $18.8 million, representing a 40% increase
over the fourth quarter 2014.
Full year 2015 revenue was $61.6 million, representing a 60% increase
over full year 2014.
Fourth quarter gross margin was 80% compared to 78%...
More
February 22, 2016 4:05 PM EST
MENLO PARK, Calif.--(BUSINESS WIRE)--
Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the
quality of life for patients with ear, nose and throat conditions, today
announced the appointment of David Lehman as general counsel. Mr. Lehman
brings three decades of legal experience to Intersect ENT, most recently
having served as general counsel and secretary for Thoratec Corporation
(NASDAQ: THOR), a global leader in medical technology to address
advanced-stage heart failure, where he saw the company through
tremendous growth and eventual sale to St. Jude... More
